score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047R	0.5141	142.0	8e-06	0.0		Putatively Actionable	Pictilisib	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828							Investigate Actionability - Low	0.0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310	0				PIK3CA p.H1047R (Missense)	1.0	MEL-IPI_Pat113	MEL-IPI_Pat113-Tumor-SM-53U2Q	MEL-IPI_Pat113-Normal-SM-4MGPR
Investigate Actionability - Low	Guideline			Somatic Variant	TET2	Missense	p.S792L	0.3947	114.0	0.0	0.0		Investigate Actionability - Low	Azacitidine	Targeted therapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf												0				TET2 p.S792L (Missense)		MEL-IPI_Pat113	MEL-IPI_Pat113-Tumor-SM-53U2Q	MEL-IPI_Pat113-Normal-SM-4MGPR
Investigate Actionability - Low	Preclinical			Copy Number	AURKB	Deletion				0.0	0.0		Investigate Actionability - Low	Barasertib	Targeted therapy	MYC amplified small cell lung cancer	Helfrich BA, Kim J, Gao D, et al. Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo. Mol Cancer Ther. 2016;15(10):2314-2322.	https://doi.org/10.1158/1535-7163.MCT-16-0298												0				AURKB Deletion		MEL-IPI_Pat113	MEL-IPI_Pat113-Tumor-SM-53U2Q	
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.D258N	0.4099	283.0	0.0	0.0																			0				NTRK2 p.D258N (Missense)		MEL-IPI_Pat113	MEL-IPI_Pat113-Tumor-SM-53U2Q	MEL-IPI_Pat113-Normal-SM-4MGPR
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.DD285del (Deletion), PRDM2 p.703_704insP (Insertion)																							0				Supporting variants: PRDM2 p.DD285del (Deletion), PRDM2 p.703_704insP (Insertion)		MEL-IPI_Pat113		
Biologically Relevant				Mutational Signature	COSMIC Signature 7		0.657																							0				COSMIC Signature 7 (66%)		MEL-IPI_Pat113		
